JPRN-jRCTs041190040招募中2 期
Randomized phase II study of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabine
Kodera Yasuhiro0 个研究点目标入组 56 人开始时间: 2019年6月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Unresectable or relapse pancreatic cancer
排除标准
- •Herbal medicine Allergies
研究者
相似试验
招募中
不适用
Randomized phase II study of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabinepatients with unresectable advanced or recurrent pancreatic cancerJPRN-UMIN000027631agoya University56
未知
2 期
Phase 2 Dose-Finding Study of JTT-305 in Patients with Primary Osteoporosis.JPRN-jRCT2080220803JAPAN TABACCO INC.320
未知
2 期
Phase II clinical study of TY-0201 in patients with chronic heart failureChronic heart failureJPRN-jRCT2080222593TOA EIYO LTD.40
进行中（未招募）
3 期
JCOG1016: Phase III randomized study for anaplastic glioma of radiotherapy with temozolomide vs. ACNU followed by temozolomideanaplastic gliomaJPRN-jRCTs031180215MURAGAKI Yoshihiro280
已完成
不适用
Phase I clinical trial of JPH203 in patients with solid cancers.Solid cancersJPRN-UMIN000016546J-Pharma Co., Ltd.21